Celiac needs machinery, not just wheat. It's an autoimmune reaction in the small intestine, and it can only start if your immune system carries one of two genes to grab gluten fragments and show them to T cells: HLA-DQ2 or HLA-DQ8. More than 99 percent of confirmed patients carry one 1. Without the gene, the reaction has nothing to hold onto. A negative test isn't a low probability; it's a missing part.
The rule-out is about as final as a test gets. The negative predictive value runs near 100 percent, and the guidelines back it for exactly that 23. A positive is weaker: it says you could have celiac, without saying you do. Risk in carriers also varies. Kids with two copies of the strongest form, DQ2.5, developed celiac autoimmunity in about 1 in 4 by age 5, versus roughly 1 in 30 for the lowest-risk DQ8 carriers 4.
The order matters more than the test. The gene test isn't the first move for someone eating gluten; it earns its place when the antibody path is blocked, usually because you're already gluten-free and won't do a six-week bread challenge to reopen it.
Four groups get the most out of it. Anyone already gluten-free without a diagnosis. First-degree relatives of a celiac patient, whose own risk runs about 1 in 13 6. People with type 1 diabetes, Down or Turner syndrome, or autoimmune thyroid disease, which share genetic territory with celiac 3. And anyone whose antibody or biopsy results don't fit. Everyone else should start with the antibody test.
The result branches into two clean futures. Negative: within days you're eating bread again, within weeks the gluten-free routine is gone, the grocery bill drops, and a source of low-grade food anxiety closes for good. Positive and confirmed: by a few months of strict eating, energy returns and iron supplements finally hold; by one to two years the gut has largely healed and long-term cancer risk falls back toward normal 7. Either way, you stop guessing.
The fine print — when to skip it, and what people get wrong
A positive is not a diagnosis. One in three Europeans carries the gene and never gets celiac 1. Going gluten-free on the gene alone confirms nothing. The test can fail to rule out; it never rules in.
Direct-to-consumer panels mislead. A "positive" or "carrier" line from an ancestry kit means the same as a clinical one: maybe, see a doctor, get antibodies.
The two common mistakes. Going gluten-free on a positive result without ever testing antibodies. And too short a gluten challenge: a slice and a half daily for two weeks is the minimum that raises antibodies, three slices for six to eight the standard 8.
- 1Karell K, Louka AS, Moodie SJ, Ascher H, Clot F, Greco L, Ciclitira PJ, Sollid LM, Partanen J (2003). HLA types in celiac disease patients not carrying the DQA1*05-DQB1*02 (DQ2) heterodimer: results from the European Genetics Cluster on Celiac Disease. Human Immunology. link
- 2Hadithi M, von Blomberg BM, Crusius JB, Bloemena E, Kostense PJ, Meijer JW, Mulder CJ, Stehouwer CD, Peña AS (2007). Accuracy of serologic tests and HLA-DQ typing for diagnosing celiac disease. Annals of Internal Medicine. link
- 3Rubio-Tapia A, Hill ID, Semrad C, Kelly CP, Greer KB, Limketkai BN, Lebwohl B (2023). American College of Gastroenterology Guidelines Update: Diagnosis and Management of Celiac Disease. American Journal of Gastroenterology. link
- 4Liu E, Lee HS, Aronsson CA, Hagopian WA, Koletzko S, Rewers MJ, Eisenbarth GS, Bingley PJ, Bonifacio E, Simell V, Agardh D (2014). Risk of Pediatric Celiac Disease According to HLA Haplotype and Country. New England Journal of Medicine. link
- 5Megiorni F, Pizzuti A (2012). HLA-DQA1 and HLA-DQB1 in Celiac disease predisposition: practical implications of the HLA molecular typing. Journal of Biomedical Science. link
- 6Singh P, Arora S, Lal S, Strand TA, Makharia GK (2015). Risk of Celiac Disease in the First- and Second-Degree Relatives of Patients With Celiac Disease: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology. link
- 7Lebwohl B, Sanders DS, Green PHR (2018). Coeliac disease. The Lancet. link
- 8Leffler D, Schuppan D, Pallav K, Najarian R, Goldsmith JD, Hansen J, Kabbani T, Dennis M, Kelly CP (2013). Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease. Gut. link
დაკავშირებული სახელმძღვანელოში (6)
- — If a food makes you feel bad, this gene test is the validated way to clear celiac — unlike the IgG panels that just flag whatever you eat.
- — Celiac travels with other autoimmune conditions. A one-time gene test rules it in or out for life.
- — A clean example of a clinical panel that rewrites care: two genes that can rule celiac out for life.
- — Like HLA-B27 for spine disease, this HLA test only earns its place once the picture already fits.
- — Celiac is a classic hidden cause of empty iron stores; this gene test helps decide whether celiac is even worth chasing.
- — A negative DQ2/DQ8 result rules celiac out for life — a fast way to clear the most important diagnosis off the table first.
HLA-DQ2/DQ8 Testing
US list price typically $200–$450 for clinical HLA-DQ2/DQ8 typing; commonly covered by insurance when a celiac evaluation indication is documented. Substantially cheaper in European public-health systems (~€50–150). One-time cost, no follow-up testing required (Rubio-Tapia et al. ACG 2023).
A single blood draw or buccal swab, no fasting, 1–2 week turnaround, lifelong result. The downstream diagnostic workup (serology, biopsy, gluten challenge) is where the burden lives — but that workup is the alternative to this test, not its consequence.
Multiple large cohort studies (Karell et al. 2003 European pool n=1,008; Hadithi et al. 2007 diagnostic-accuracy study; Liu et al. 2014 TEDDY prospective n=6,403) establish the ~99.6% sensitivity and near-100% negative predictive value across populations. Aligned ESPGHAN 2020 and ACG 2023 guidelines endorse the test for rule-out and family-screening indications. Mechanism (DQ2/DQ8-restricted gliadin presentation) is fully characterized (Sollid and Jabri 2013).
For the patient who turns out to have celiac, a confirmed diagnosis followed by a strict gluten-free diet produces clear short-term improvement in GI symptoms, fatigue, and iron status within weeks to months (Rubio-Tapia et al. ACG 2023). For the gluten-avoiding patient with a negative HLA result, the immediate payoff is release from an unnecessary dietary restriction. Real but population-averaged effect.
Undiagnosed celiac modestly elevates all-cause mortality and substantially elevates risk of small-bowel adenocarcinoma and enteropathy-associated T-cell lymphoma; strict gluten-free diet returns mortality and cancer risk toward population baseline (Lebwohl et al. 2018). Test value is conditional on positive serology follow-through and dietary adherence.
Untreated celiac frequently causes iron-deficiency anemia and chronic fatigue from malabsorption; diagnosis and a gluten-free diet substantially restore daily energy in symptomatic patients (Lebwohl et al. 2018). For the negative-result patient, no energy effect.
Indirect: if the test leads to a celiac diagnosis and adherence to a gluten-free diet, untreated celiac sequelae like dermatitis herpetiformis, pallor from iron-deficiency anemia, brittle nails, and telogen effluvium can reverse over months (Lebwohl et al. 2018). Conditional on disease — the population-level cumulative beauty effect of testing alone is small.
A meaningful subset of celiac patients report brain fog that improves on a gluten-free diet, though high-quality trial data on cognitive endpoints are limited (Lebwohl et al. 2018). Effect is real but indirect and smaller than the GI/energy axis.
Resolving the open question of whether one has celiac removes a real source of food anxiety. Diagnosed celiac is also associated with elevated rates of depression and anxiety that partially resolve with a strict gluten-free diet (Lebwohl et al. 2018). Effect is modest and conditional.